- In the ongoing Phase 3 GEMSTONE-301 study, sugemalimab administered after treatment with either concomitant or sequential chemoradiation therapy demonstrated a statistically significant improvement in progression-free survival compared to placebo in patients with unresectable non-small cell lung cancer (NSCLC). Stage III.
- There are currently no immunotherapy consolidation regimens approved in the US or Europe for patients with unresectable stage III NSCLC who have received sequential chemoradiotherapy
CAMBRIDGE, Mass., Aug. 7, 2022 (GLOBE NEWSWIRE) — EQRx, Inc. EQRXa novel pharmaceutical company committed to developing and delivering innovative medicines at radically lower prices, today announced a landmark oral presentation of updated data from the Phase 3 GEMSTONE-301 study of sugemalimab in non-small cell lung cancer (NSCLC) at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC), taking place August 6-9, 2022. These results will be presented in the WCLC press program.
“In the updated results of GEMSTONE-301, sugemalimab demonstrated a sustained benefit for progression-free survival, underscoring its potential as a consolidation therapy for people with locally advanced, unresectable, stage III non-small cell lung cancer,” said Vince Miller, MD, Physician – boss at EQRx. “The inclusion of patients who received sequential chemoradiotherapy in this study is of particular importance as patients often cannot tolerate concomitant chemoradiotherapy or cannot access it due to various factors. There is currently no approved immune checkpoint inhibitor as a consolidation option for these patients, who are estimated to represent up to 25% of people with unresectable stage III non-small cell lung cancer in the United States.”
At the March 2022 data cut-off, the final progression-free survival (PFS) analysis of the phase 3 GEMSTONE-301 study showed that sugemalimab continues to…